A P Coletta

Summary

Affiliation: University of Hull
Country: UK

Publications

  1. ncbi Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. As
    Amala A Louis
    Department of Academic Cardiology, Castle Hill Hospital, Cottingham, HU16 5JQ, Kingston upon Hull, UK
    Eur J Heart Fail 4:111-6. 2002
  2. pmc Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK
    Eur J Heart Fail 11:214-9. 2009
  3. ncbi Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 8:547-9. 2006
  4. ncbi Clinical trials update from the joint European Society and World Congress of Cardiology meeting: PEP-CHF, ACCLAIM and the HHH study
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 8:658-61. 2006
  5. ncbi Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull HU15 5JQ, UK
    Eur J Heart Fail 5:697-704. 2003
  6. ncbi Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, HU15 5JQ, Kingston upon Hull, UK
    Eur J Heart Fail 5:545-8. 2003
  7. doi Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 10:917-20. 2008
  8. ncbi Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure
    A P Coletta
    Department of Academic Cardiology, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK
    Eur J Heart Fail 5:95-9. 2003
  9. ncbi Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II
    A P Coletta
    Department of Academic Cardiology, University of Hull, Castle Hull Hospital, Kingston upon Hull HU15 5JQ, Cottingham, UK
    Eur J Heart Fail 4:661-6. 2002
  10. ncbi Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH
    A P Coletta
    Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 4:559-61. 2002

Detail Information

Publications31

  1. ncbi Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. As
    Amala A Louis
    Department of Academic Cardiology, Castle Hill Hospital, Cottingham, HU16 5JQ, Kingston upon Hull, UK
    Eur J Heart Fail 4:111-6. 2002
  2. pmc Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK
    Eur J Heart Fail 11:214-9. 2009
    ..ix) A secondary analysis from ATHENA showed a reduction in cardiovascular hospitalizations and strokes for patients with atrial fibrillation receiving dronedarone compared with placebo...
  3. ncbi Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 8:547-9. 2006
    ..In a combined analysis of two studies (n=186), the adenosine A(1) receptor antagonist KW-3902 showed diuretic properties and appeared to enhance response to loop diuretics in heart failure patients hospitalised with fluid overload...
  4. ncbi Clinical trials update from the joint European Society and World Congress of Cardiology meeting: PEP-CHF, ACCLAIM and the HHH study
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 8:658-61. 2006
    ..The HHH study failed to show a beneficial effect of telemonitoring over usual care in patients with heart failure but potentially important country interactions were observed...
  5. ncbi Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull HU15 5JQ, UK
    Eur J Heart Fail 5:697-704. 2003
    ..The ESTEEM study showed that the oral thrombin inhibitor ximelagatran plus aspirin was more effective than aspirin alone in the prophylaxis of major cardiovascular events following MI...
  6. ncbi Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, HU15 5JQ, Kingston upon Hull, UK
    Eur J Heart Fail 5:545-8. 2003
    ..The SHAPE survey of heart failure awareness in Europe identified a need for further heart failure education amongst the public, patients, their carers and primary care physicians...
  7. doi Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 10:917-20. 2008
    ..The selective myosin activator CK-1827452 produced a concentration dependent increase in systolic ejection time, stroke volume and fractional shortening in patients with heart failure compared to placebo...
  8. ncbi Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure
    A P Coletta
    Department of Academic Cardiology, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK
    Eur J Heart Fail 5:95-9. 2003
    ....
  9. ncbi Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II
    A P Coletta
    Department of Academic Cardiology, University of Hull, Castle Hull Hospital, Kingston upon Hull HU15 5JQ, Cottingham, UK
    Eur J Heart Fail 4:661-6. 2002
    ..Summaries of the results of the following trials are presented: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II...
  10. ncbi Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH
    A P Coletta
    Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 4:559-61. 2002
    ..Summaries of the results of the RENEWAL (RENAISSANCE and RECOVER) and ATTACH studies, presented at the Hot Line sessions held during the meeting are reported...
  11. doi Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF
    Alison P Coletta
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 10:1264-7. 2008
    ..In the HOME-HF study, telemonitoring support failed to reduce the time to first re-hospitalisation or death, or days alive and out of hospital, compared with usual care...
  12. ncbi Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy
    Alison P Coletta
    Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 6:673-6. 2004
    ..1% and +12.0%, respectively). Revised mortality data for the CASINO study and a meta-analysis of the effects of cardiac resynchronisation therapy on mortality in the light of the recently published COMPANION study are reported...
  13. ncbi Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME
    A P Coletta
    Department of Academic Cardiology, Castle Hill Hospital, Cottingham, HU16 5JQ, Kingston upon Hull, UK
    Eur J Heart Fail 3:747-50. 2001
    ..Summaries of the following clinical studies are included: WARIS-II, ESCAMI, PAFAC, RITZ-I and TIME...
  14. ncbi Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 6:787-91. 2004
    ..The primary outcome measure is death or hospitalisation for any reason...
  15. ncbi Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans
    John G F Cleland
    Department of Academic Cardiology, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK
    Eur J Heart Fail 5:391-8. 2003
    ..T-wave alternans is an interesting experimental technique that may be useful in selecting which patients need an implantable defibrillator, although the technology needs testing in an appropriate patient population...
  16. doi Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 10:102-8. 2008
    ..Three trials of stem cell therapy in post-MI patients gave conflicting results...
  17. ncbi Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 9:1070-3. 2007
    ..Low dose atorvastatin reduced the incidence of sudden cardiac death in a small placebo controlled study of patients with advanced chronic heart failure...
  18. ncbi Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 9:850-3. 2007
    ..AREA-IN-CHF failed to show a beneficial effect of canrenone on LV volumes compared to placebo however some beneficial effects on secondary clinical endpoints were observed...
  19. ncbi Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 9:740-5. 2007
    ..A large study of BNP provided additional information on its ability to distinguish cardiac and pulmonary breathlessness. The importance of dietary intervention in post-MI patients was highlighted by the findings of THIS-diet study...
  20. ncbi A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 6:1-2. 2004
  21. ncbi Clinical trials update from the American Heart Association meeting: Omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT an
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 6:109-15. 2004
    ..ORBIT and PAD showed public access defibrillators saved lives but questioned their cost effectiveness. DEFINITE supported a role for ICDs in patients with non-ischemic cardiomyopathy, although cost-effectiveness remains in doubt...
  22. ncbi Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 8:326-9. 2006
    ..The ICELAND MI study showed that CMR imaging was more sensitive than ECG or clinical criteria for detecting myocardial infarction...
  23. ncbi Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD
    Krishna Lalukota
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 6:953-5. 2004
    ....
  24. ncbi Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost-effectiveness study
    Rhidian J Shelton
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 7:127-35. 2005
    ..Analysis of data from SCD-HeFT supports the cost-effectiveness of ICDs in heart failure, although overall cost implications may be prohibitive...
  25. ncbi Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK
    Eur J Heart Fail 6:501-8. 2004
    ..Rimonabant was shown to be safe and effective in treating the combined cardiovascular risk factors of smoking and obesity. An overview of new developments in cardiac resynchronisation therapy (CRT) in heart failure is also reported...
  26. ncbi Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 7:931-6. 2005
    ..In the PREMIER study the matrix metalloproteinase inhibitor PG-116800 failed to prevent LV remodelling following myocardial infarction...
  27. ncbi Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK
    Eur J Heart Fail 7:1070-5. 2005
    ..The ACTIVE W study of warfarin versus aspirin plus clopidogrel in atrial fibrillation has been stopped due to superiority of warfarin...
  28. ncbi Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 8:105-10. 2006
    ..The PROACTIVE study showed encouraging results for the use of pioglitazone in post-myocardial infarction patients with concomitant type 2 diabetes...
  29. ncbi Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 7:937-9. 2005
    ....
  30. ncbi Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty
    John G F Cleland
    Department of Cardiology, Postgraduate Medical Institute, Division of Cardiovascular and Respiratory Studies, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK
    Eur J Heart Fail 9:92-7. 2007
    ..In IMPROVE-CHF, an NT-pro BNP guided treatment strategy was found to reduce the cost of managing patients with acute breathlessness...
  31. ncbi Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK
    Eur J Heart Fail 8:764-6. 2006
    ..In OPT-CHF, oxypurinol failed to show benefit compared to placebo for the treatment of heart failure, although a retrospective subgroup analysis suggests that it may be beneficial in patients with elevated serum uric acid levels...